行情

MYOK

MYOK

MyoKardia
NASDAQ

实时行情|Nasdaq Last Sale

66.70
+1.43
+2.19%
盘后: 66.70 0 0.00% 17:00 12/13 EST
开盘
65.27
昨收
65.27
最高
67.09
最低
65.27
成交量
28.03万
成交额
--
52周最高
68.60
52周最低
39.01
市值
30.83亿
市盈率(TTM)
-12.7854
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MYOK 新闻

  • 气候变化将对人类重要野生蔬菜构成灭绝威胁
  • 新浪财经综合.3小时前
  • 专家警告日本“绝种”风险!韩国问题更严重
  • 新浪财经综合.3小时前
  • 美政府调查第12起涉及特斯拉Autopilot交通事故
  • 新浪科技.3小时前
  • 英首相:回报选民信任的最好方式是尽快完成“脱欧”
  • 央视.4小时前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

MYOK 简况

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
展开

Webull提供Myokardia Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。